Sex steroids in androgen-secreting adrenocortical tumors: clinical and hormonal features in comparison with non-tumoral causes of androgen excess
| Autor: | Jérôme Bertherat, Lionel Groussin, Vivian Viallon, Gwenaelle Abiven-Lepage, Marie Annick Dugué, Catarina B d'Alva, Xavier Bertagna |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent Hydrocortisone medicine.drug_class Endocrinology Diabetes and Metabolism Androgen Excess Sensitivity and Specificity Basal (phylogenetics) Endocrinology Internal medicine Biomarkers Tumor Humans Medicine Testosterone Androstenedione Acne hirsutism Aged Retrospective Studies Aged 80 and over Dehydroepiandrosterone Sulfate business.industry Reproducibility of Results Estrogens General Medicine Luteinizing Hormone Middle Aged medicine.disease Androgen Adrenal Cortex Neoplasms Androgens Female Amenorrhea Follicle Stimulating Hormone medicine.symptom business |
| Zdroj: | European Journal of Endocrinology. 159:641-647 |
| ISSN: | 1479-683X 0804-4643 |
| Popis: | ObjectiveAdrenocortical tumors (ACT) account for no more than 0.2% of the causes of androgen excess (AE). Conversely, these rare tumors have a very poor prognosis. It is difficult and important to exclude this diagnosis whenever there is AE.DesignRetrospective investigation of androgen profiles in a large consecutive series of androgen-secreting (AS) ACT to assess their relative diagnostic value.MethodsA total of 44 consecutive female patients with ACT-AS and a comparison group of 102 women with non-tumor causes of AE (NTAE).ResultsPatients with ACT-AS were older than the ones with NTAE (37.7 vs 24.8 years; PConclusionFree testosterone was the most reliable marker of ACT-AS. However, the large overlap of androgen levels between ACT-AS and NTAE groups suggests that additional hormonal and/or imaging investigations are required to rule out ACT-AS in case of increased androgens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|